X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aurobindo Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
ADCOCK INGRAM
Jun-14
AUROBINDO PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs895377-   
Low Rs622272-   
Sales per share (Unadj.) Rs254.6112.1-  
Earnings per share (Unadj.) Rs39.3-28.3-  
Cash flow per share (Unadj.) Rs46.6-23.4-  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs160.088.0-  
Shares outstanding (eoy) m585.88168.78-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.02.9 103.0%   
Avg P/E ratio x19.3-11.5 -168.2%  
P/CF ratio (eoy) x16.3-13.9 -117.5%  
Price / Book Value ratio x4.73.7 128.6%  
Dividend payout %6.40-   
Avg Mkt Cap Rs m444,39054,766 811.4%   
No. of employees `00014.04.3 325.7%   
Total wages/salary Rs m17,6783,437 514.3%   
Avg. sales/employee Rs Th10,667.84,409.0 242.0%   
Avg. wages/employee Rs Th1,264.3800.7 157.9%   
Avg. net profit/employee Rs Th1,645.8-1,111.0 -148.1%   
INCOME DATA
Net Sales Rs m149,15718,928 788.0%  
Other income Rs m1,159133 874.3%   
Total revenues Rs m150,31619,061 788.6%   
Gross profit Rs m34,343-3,280 -1,047.0%  
Depreciation Rs m4,276817 523.5%   
Interest Rs m667513 130.1%   
Profit before tax Rs m30,558-4,477 -682.5%   
Minority Interest Rs m50-12 -402.2%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,597280 2,715.4%   
Profit after tax Rs m23,012-4,769 -482.5%  
Gross profit margin %23.0-17.3 -132.9%  
Effective tax rate %24.9-6.2 -397.8%   
Net profit margin %15.4-25.2 -61.2%  
BALANCE SHEET DATA
Current assets Rs m92,06213,863 664.1%   
Current liabilities Rs m66,2237,800 849.0%   
Net working cap to sales %17.332.0 54.1%  
Current ratio x1.41.8 78.2%  
Inventory Days Days106111 95.6%  
Debtors Days Days68124 54.6%  
Net fixed assets Rs m62,9198,081 778.6%   
Share capital Rs m58688 666.7%   
"Free" reserves Rs m93,1330-   
Net worth Rs m93,71914,856 630.8%   
Long term debt Rs m1,8145,221 34.7%   
Total assets Rs m162,49428,065 579.0%  
Interest coverage x46.8-7.7 -605.3%   
Debt to equity ratio x00.4 5.5%  
Sales to assets ratio x0.90.7 136.1%   
Return on assets %14.6-15.2 -96.1%  
Return on equity %24.6-32.1 -76.5%  
Return on capital %32.7-19.8 -165.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m45,6130-   
CASH FLOW
From Operations Rs m32,7861,616 2,029.3%  
From Investments Rs m-17,870-496 3,602.3%  
From Financial Activity Rs m-19,1534,738 -404.2%  
Net Cashflow Rs m-4,2395,858 -72.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.2 Rs / ZAR

Compare AUROBINDO PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: TORRENT PHARMA  PFIZER  JUBILANT LIFE SCIENCES  SHASUN PHARMA  WYETH LTD  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 17, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS